Methods and compositions for reducing symptoms of Parkinson's disease
AssigneeNeuroDerm, Ltd.
InventorsLiat Adar, Nelson Felix Lopes, Laurence Salin, Tamar Yardeni, Nissim Sasson, Sheila Oren, Hikari Yarita, Mikio Himizu, Natalia Vostokova
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Claims29
A method of treating a patient with Parkinson's disease, the method comprising subcutaneously administering to the patient, substantially continuously for about 24 hours/day and for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa and carbidopa in a ratio of about 8:1 w/w, and further comprising arginine,
- wherein by the third consecutive day the administration results in the patient having at least one of:
- an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time,
- a reduction from baseline of at least about 0.3 to 2.5 hours in daily ON-time with moderate-severe dyskinesia,
- a reduction from baseline of at least 0.1 to 2.0 hours in daily OFF-time,
- an increase from baseline of at least about 0.1 to 3.5 hours in daily ON-time without dyskinesia,
- a reduction from baseline of at least 0.1 to 3.2 hours in total daily troublesome dyskinesia,
- an improvement from baseline in motor experiences of daily living, as assessed by the Movement Disorder Society-Sponsored revision of Unified Parkinson's Disease Rating Scale Part III (UPDRS Part III) score, resulting in a reduction from baseline of about 2 to 13 points in the UPDRS Part III score,
- or any combination thereof.
A method of treating a patient with Parkinson's disease, the method comprising subcutaneously administering to the patient, substantially continuously for about 24 hours/day and for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa, carbidopa, and arginine,
- wherein the pharmaceutically acceptable liquid composition comprises about 60 mg/ml levodopa and 7.5 mg/mL carbidopa, and wherein the pharmaceutically acceptable liquid composition is administered to deliver about 720 mg of levodopa and about 90 mg of carbidopa to the patient over the course of about 24 hours,
- wherein by the third consecutive day the administration results in the patient having at least one of:
- an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time,
- a reduction from baseline of at least about 0.3 to 2.5 hours in daily ON-time with moderate-severe dyskinesia,
- a reduction from baseline of at least 0.1 to 2.0 hours in daily Off time,
- an increase from baseline of at least about 0.1 to 3.5 hours in daily ON-time without dyskinesia,
- a reduction from baseline of at least 0.1 to 3.2 hours in total daily troublesome dyskinesia,
- a reduction from baseline of about 2 to 13 points in UPDRS Part III scores,
- or any combination thereof.
A method of increasing Good ON-time in a patient with Parkinson's disease, the method comprising
- subcutaneously administering to the patient, substantially continuously for about 24 hours/day for about 2 to 3 consecutive days, a pharmaceutically acceptable liquid composition comprising levodopa and carbidopa, in a ratio of about 8:1 w/w, and further comprising arginine,
- wherein by the third consecutive day the administration results in an increase from baseline of at least about 0.3 to 3.5 hours in daily Good ON-time.
Dependencies are inferred from the claim text.